University of California San Francisco
Helen Diller Family Comprehensive Cancer Center

Clinical Trials

Gastrointestinal Oncology UCSF

Thank you for your interest in GI clinical trials at UCSF.

Research studies conducted with cancer patients are called clinical trials. As a cancer patient, you may take part in a clinical trial.

Please see the links below for current open trials at UC San Francisco.

Colorectal | Early Phase | Gastro Esophageal | Hepatocellular and Biliary Tract
| ImmunotherapyNeuroendocrine | Non-therapeutic | Pancreatic
Opening Soon | All Cancer Trials at UCSF

COLORECTAL

 

CC#16452: Phase I Study of TAS-102 (Lonsurf) and Radioembolization with 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases

Contact: Alexandra (Alex) Milloy (415) 502-3310: Alexandra.Milloy@ucsf.edu

 

CC#16702: A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers (MSI-H colorectal carcinomas)

Contact: Dhruba Biswas (415) 514-2259: Dhruba.Biswas@ucsf.edu 

 

CC#169517: A Phase 1 Dose Escalation Study, with Cohort Expansion, to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AbGn-107 Therapy in Patients with Chemo-refractory Locally Advanced, Recurrent, or Metastatic Gastric, Colorectal, Pancreatic or Biliary Cancer

Contact: Malori Mindo (415) 502-6313: Malori.Mindo@ucsf.edu

 

CC#174517: Phase II Study of Pembrolizumab Plus Capecitabine and Bevacizumab in Microsatellite Stable Metastatic Colorectal Cancer

Contact: Renee Wang (415) 514-6258: Renee.Wang@ucsf.edu 

 

CC#174528: A Study of Nivolumab in Combination With Trametinib or Without Ipilimumab in Participants With Previously Treated Metastatic Colorectal Cancers

Contact: Faaiz Ibrahim (415) 514-8101: Faaiz.Ibrahim@ucsf.edu

 

CC#177015: A Phase 1A/1B Open-Label, Dose Escalation Study of the Safety and Pharmacokinetics of RO7198457 as a Single Agent and in Combination With Atezolizumab in Patients with Locally Advanced or Metastatic Tumors

Contact: Sophia Bylsma (415) 502-4760: Sophia.Bylsma@ucsf.edu

 

CC#189516: A Phase 1b Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors Subjects with locally advanced (unresectable) or metastatic solid tumor malignancy including but not limited to SCCHN, NSCLC, metastatic castration resistant prostate cancer (mCRPC), ovarian cancer, colorectal cancer (CRC) and gastric cancer, who have received prior therapy.

Contact: Ro Rahimi (415) 514-6674: Roshun.Rahimi@ucsf.edu

 

CC#187015: A Phase II Study of Preoperative Immunotherapy in Patients with Colorectal Cancer and Resectable Hepatic Metastases

Contact: Rebecca Holman (415) 476-2958; Rebecca.Holman@ucsf.edu

   

  

 

  

 

 

EARLY PHASE

     

AMC095: A phase 1 study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors with an Expansion Cohort in HIV Associated Solid Tumors

Contact: Erika Zigman (415) 353-7381: Erika.Zigman@ucsf.edu

  

CC#169517: A Phase 1 Dose Escalation Study, with Cohort Expansion, to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AbGn-107 Therapy in Patients with Chemo-refractory Locally Advanced, Recurrent, or Metastatic Gastric, Colorectal, Pancreatic or Biliary Cancer

Contact: Malori Mindo (415) 502-6313: Malori.Mindo@ucsf.edu

  

CC#169519: A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors (only SCLC and TNBC)

Contact: Erika Zigman (415) 353-7381: Erika.Zigman@ucsf.edu 

 

CC#169521: Combination Therapy of Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair (Note: restricted to patients with defects in the following molecules: BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK2, FANCA, NBN, PALB2, RAD51, RAD51B, RAD51C, RAD51D, RAD54L)

Contact: Ro Rahimi (415) 514-6674: Roshun.Rahimi@ucsf.edu

 

CC#169524: A Pilot Study of Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas

Contact: Melissa Lopez (415) 885-3728: Melissa.Lopez@ucsf.edu

  

CC#17955: A Phase 1, Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of CBT-101 in Subjects with Advanced Solid Tumors and c- Met Dysregulation.

** Study on hold due to manufacturing issues **

Contact: Melissa Lopez (415) 885-3728: Melissa.Lopez@ucsf.edu

 

CC#18952: A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies

Contact: Claire Hooker (415) 353-7084: Claire.Hooker@ucsf.edu 

 

CC#18955: A Phase 1 / 2 Study of Olaparib in Combination with Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

Contact: Claire Hooker (415) 353-7084: Claire.Hooker@ucsf.edu 

 

CC#18956: A Phase 1B Dose Escalation/Expansion Study of Abexinostat in Combination with Pembrolizumab in Patients with Advanced Solid Tumor Malignancies

Contact: Ro Rahimi (415) 514-6674: Roshun.Rahimi@ucsf.edu

 

CC#18959: Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematologic Malignancies or Solid Tumors

** Study on hold due to manufacturing issues **

Contact: Pranay Chaurasia (415) 885-3724: Pranay.Chaurasia@ucsf.edu

 

CC#189510: Phase II Trial of AZD6738 Alone and in Combination with Olaparib in Patients with Selected Solid Tumor Malignancies

Contact: Claire Hooker (415) 353-7084: Claire.Hooker@ucsf.edu 

 

CC#189511: A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb20717 in Subjects with Selected Advanced Solid Tumors (DUET-2)

Contact: Lauren Wilch (phone number pending): Lauren.Wilch@ucsf.edu

 

CC#17956: A Phase 1 Study of LY3200882 in Patients with Solid Tumor

Contact: Claire Hooker (415) 353-7084: Claire.Hooker@ucsf.edu 

 

CC#189513: A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of mRNA-5671/V941 as a Monotherapy and IN combination with Pembrolizumab in Participants with KRAS Mutant Advanced or Metastatic Non-Small Cell Lung Cancer, Colorectal Cancer or Pancreatic Adenocarcinoma

Contact: Melissa Lopez (415) 885-3728: Melissa.Lopez@ucsf.edu 

 

CC#189514: A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of RMC-4630 Monotherapy in Adult Participants with Relapsed/Refractory Solid Tumors RMC-4630 is a potent, selective, and orally bioavailable SHP2 allosteric inhibitor that is being developed for patients with tumors harboring certain activating mutations or other genotypic aberrations in the RAS–MAPK pathway, including upstream mutations in RTKs.

Contact: Melissa Lopez (415) 885-3728: Melissa.Lopez@ucsf.edu 

 

CC#189515: A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Subjects With Advanced Solid Tumors with a Specific KRAS Mutation

Contact: Ro Rahimi (415) 885-3728: Roshun.Rahimi@ucsf.edu

 

CC#189516: A Phase 1b Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors Subjects with locally advanced (unresectable) or metastatic solid tumor malignancy including but not limited to SCCHN, NSCLC, metastatic castration resistant prostate cancer (mCRPC), ovarian cancer, colorectal cancer (CRC) and gastric cancer, who have received prior therapy.

Contact: Ro Rahimi (415) 514-6674: Roshun.Rahimi@ucsf.edu

 

CC#189519: An Open-Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination with Carboplatin to Assess Safety, Tolerability, and

Pharmacokinetics in Patients with Advanced or Metastatic Solid Tumors

Contact: Lily Stander (phone number pending): Lily.Stander@ucsf.edu  

 

CC#19952: A Phase II Basket Study of Oral Selective Pan-FGFR Inhibitor Debio 1347 in Subjects With Solid Tumors Harboring a Fusion of FGFR1, FGFR2, or FGFR3

Contact: Pranay Chaurasia (415) 885-3724: Pranay.Chaurasia@ucsf.edu

 

CC#19954:  A Phase 1 Multicenter, Open-Label, Dose-Escalation an Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Antitumor Activity of AO_176

Contact: Erika Zigman (415) 353-7381: Erika.Zigman@ucsf.edu 

 

CC#19955: Protocol 101-18101 – An Open Label Phase 1b Study of ORIC-101 in Combination with Anticancer Therapy in Patients with Advanced or Metastatic Solid Tumors

Contact: Erika Zigman (415) 353-7381: Erika.Zigman@ucsf.edu 

 


 

GASTRO ESOPHAGEAL

 

CC#169517: A Phase 1 Dose Escalation Study, with Cohort Expansion, to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AbGn-107 Therapy in Patients with Chemo-refractory Locally Advanced, Recurrent, or Metastatic Gastric, Colorectal, Pancreatic or Biliary Cancer

Contact: Malori Mindo (415) 502-6313: Malori.Mindo@ucsf.edu

 

CC#17701: A Pilot Study of APX005M in Combination With Concurrent Chemoradiation as Neoadjuvant Therapy for Resectable Esophageal and Gastroesophageal Junction Cancers

Contact: Marissa Gin (415) 476-3816: Marissa.Gin@ucsf.edu

 

CC#18453: A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of IMAB362 Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-Line Treatment of Subjects with Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced, Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Contact: Mikaela Esquivel (415) 353-7145: Mikaela.Esquivel@ucsf.edu

 

CC#18955: A Phase 1 / 2 Study of Olaparib in Combination with Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

Contact: Claire Hooker (415) 353-7084: Claire.Hooker@ucsf.edu 

 

CC#189516: A Phase 1b Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors Subjects with locally advanced (unresectable) or metastatic solid tumor malignancy including but not limited to SCCHN, NSCLC, metastatic castration resistant prostate cancer (mCRPC), ovarian cancer, colorectal cancer (CRC) and gastric cancer, who have received prior therapy.

Contact: Ro Rahimi (415) 514-6674: Roshun.Rahimi@ucsf.edu

 

 

  
 

HEPATOCELLULAR and BILIARY TRACT

  

CC#15452: A Phase II Multicenter, Single Arm Study of Oral BGJ398 in Adult Patients with Advanced or Metastatic Cholangiocarcinoma with FGFR2 Gene Fusions or Other FGFR Genetic Alterations Who Failed or Are Intolerant To Platinum-Based Chemotherapy

Contact: Lillian Jahan (415) 502-4174: Lillian.Jahan@ucsf.edu

 

CC#154524: A Phase II Trial of Pembrolizumab (MK-3475) with GM-CSF Induction in Advanced Biliary Cancers

Contact: Brenna Sheldon (415) 476-5442: Brenna.Sheldon@ucsf.edu

 

CC#16451: A Study of Safety, Tolerability, and Clinical Activity of MEDI4736 and Tremelimumab Administered as Monotherapy and in Combination to Subjects with Unresectable Hepatocellular Carcinoma

Contact: Madeline Griffith (415) 476-7974: Madeline.Griffith@ucsf.edu

 

CC#164514: Phase I Dose-Escalating Study of Combining Tirapazamine and Transarterial Embolization in Hepatocellular Carcinoma

Contact: Katherine Wu (415) 353-9437: Katherine.Wu@ucsf.edu

 

CC#17457: A Dose-Finding Phase 1 Study of TAS-120 in Patients With Advanced Solid Tumors With or Without Fibroblast Growth Factor/Receptor (FGF/FGFR)-Related Abnormalities followed by a Phase 2 Study in Patients with Advanced Solid Tumors with FGF/FGFR-Related Abnormalities

Contact: Lillian Jahan (415) 502-4174: Lillian.Jahan@ucsf.edu

 

CC#174523: A Multicenter Pilot Study of the Safety, Efficacy, and Immune Cell Profiling in Advanced Hepatocellular Carcinoma (HCC) Patients Treated with the Combination of Sorafenib plus Nivolumab as First-Line of Systemic Therapy

Contact: Brenna Sheldon (415) 476-5442: Brenna.Sheldon@ucsf.edu

 

CC#174532: A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients with Unresectable Hepatocellular Carcinoma (HIMALAYA)

Contact: Madeline Griffith (415) 476-7974: Madeline.Griffith@ucsf.edu

 

CC#177015: A Phase 1A/1B Open-Label, Dose Escalation Study of the Safety and Pharmacokinetics of RO7198457 as a Single Agent and in Combination With Atezolizumab in Patients with Locally Advanced or Metastatic Tumors

Contact: Sophia Bylsma (415) 502-4760: Sophia.Bylsma@ucsf.edu

 

CC#184517: A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy

Contact: Maxine Hamilton (415) 476-3755: Maxine.Hamilton@ucsf.edu

 

S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers

Contact: Lillian Jahan (415) 502-4174: Lillian.Jahan@ucsf.edu

 

CC#19453: A Phase II, Multicenter, Open-label Study to Investigate the Clinical Efficacy of M7824 Monotherapy in Participants With Locally Advanced or Metastatic Biliary Tract Cancer Who Fail or are Intolerant to First-line Platinum-Based Chemotherapy

Contact: Gar Singer (415) 353-9544: Gar.Singer@ucsf.edu

 

 

IMMUNOTHERAPY

 

CC#16702: A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers (MSI-H colorectal carcinomas)

Contact: Dhruba Biswas (415) 514-2259: Dhruba.Biswas@ucsf.edu 

 

CC#17701: A Pilot Study of APX005M in Combination With Concurrent Chemoradiation as Neoadjuvant Therapy for Resectable Esophageal and Gastroesophageal Junction Cancers

Contact: Marissa Gin (415) 476-3816: Marissa.Gin@ucsf.edu

 

CC#17705: A Pilot Study of Pembrolizumab and Liver-Directed Therapy For Patients With Well-Differentiated Neuroendocrine Tumors and Symptomatic and/or Progressive Liver Metastases

Contact: Caroline Nattinger (415) 502-8075: Caroline.Nattinger@ucsf.edu

 

CC#17709: Open-label, Multicenter, Phase 1b/2 Clinical Study to Evaluate the Safety and Efficacy of CD40 Agonistic Monoclonal Antibody (APX005M) Administered Together With Gemcitabine and Nab-Paclitaxel With or Without PD-1 Blocking Antibody (Nivolumab) in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma

Contact: Marissa Gin (415) 476-3816: Marissa.Gin@ucsf.edu

 

CC#177015: A Phase 1A/1B Open-Label, Dose Escalation Study of the Safety and Pharmacokinetics of RO7198457 as a Single Agent and in Combination With Atezolizumab in Patients with Locally Advanced or Metastatic Tumors

Contact: Sophia Bylsma (415) 502-4760: Sophia.Bylsma@ucsf.edu

 

 

NEUROENDOCRINE TUMORS

 

CC#169524: A Pilot Study of Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas

Contact: Melissa Lopez (415) 885-3728: Melissa.Lopez@ucsf.edu

 

CC#17459: Phase II Randomized Embolization Trial for Neuroendocrine Tumor Metastases To The Liver (RETNET) 

Contact: Wendy Ma (415) 514-4418 : Wendy.Ma@ucsf.edu

 

CC#17705: A Pilot Study of Pembrolizumab and Liver-Directed Therapy For Patients With Well-Differentiated Neuroendocrine Tumors and Symptomatic and/or Progressive Liver Metastases

Contact: Caroline Nattinger (415) 502-8075: Caroline.Nattinger@ucsf.edu

 

A021602: Randomized, Double-Blinded Phase III Study of Cabozantinib Versus Placebo in Patients With Advanced Neuroendocrine Tumors After Progression On Everolimus (CABINET)

Contact: Alexandra (Alex) Milloy (415) 502-3310: Alexandra.Milloy@ucsf.edu

 

 

NON-THERAPEUTIC

 

CC#164519: Circulating Tumor Derived Cell-Free DNA as a Novel Biomarker to Predict Recurrence of Colorectal Cancer

Contact: Faaiz Ibrahim (415) 514-8101: Faaiz.Ibrahim@ucsf.edu

 

CC#174525: Self-Monitoring and Reminder Texts for Physical Activity After Cancer II (Smart Pace II)

Contact: Paige Steiding (415) 514-6314: Paige.Steiding@ucsf.edu

 

CC#174527: GO – Gut Microbiome and Oral Fluoropyrimidine Study in Patients with Colorectal Cancer

Contact: Dalila Stanfield (phone number pending): Dalila.Stanfield@ucsf.edu  

 

CC#18454: Predictors of Response to Systemic Therapy In Pancreatic Cancer

Contact: Alexandra (Alex) Milloy (415) 502-3310: Alexandra.Milloy@ucsf.edu

  

 

 

PANCREATIC

 

CC#169517: A Phase 1 Dose Escalation Study, with Cohort Expansion, to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AbGn-107 Therapy in Patients with Chemo-refractory Locally Advanced, Recurrent, or Metastatic Gastric, Colorectal, Pancreatic or Biliary Cancer

Contact: Malori Mindo (415) 502-6313: Malori.Mindo@ucsf.edu

 

CC#17709: Open-label, Multicenter, Phase 1b/2 Clinical Study to Evaluate the Safety and Efficacy of CD40 Agonistic Monoclonal Antibody (APX005M) Administered Together With Gemcitabine and Nab-Paclitaxel With or Without PD-1 Blocking Antibody (Nivolumab) in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma

Contact: Marissa Gin (415) 476-3816: Marissa.Gin@ucsf.edu

 

CC#174512: A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-based Treatment Combinations in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (MORPHEUS-Pancreatic Cancer) 

Contact: Mikaela Esquivel (415) 353-7145: Mikaela.Esquivel@ucsf.edu

 

CC#189513: A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of mRNA-5671/V941 as a Monotherapy and IN combination with Pembrolizumab in Participants with KRAS Mutant Advanced or Metastatic Non-Small Cell Lung Cancer, Colorectal Cancer or Pancreatic Adenocarcinoma

Contact: Melissa Lopez (415) 885-3728: Melissa.Lopez@ucsf.edu 

 

 

************************************************** 

 

**TO BE OPENED WITHIN 3 MONTHS**

 

CC#184519: Cell Free DNA and Imaging in Advanced Gastrointestinal Cancers

Contact: Malori Mindo (415) 502-6313: Malori.Mindo@ucsf.edu

 

CC#19457: Phase I/II Trial of Encorafenib, Cetuximab, and Nivolumab in Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer

Contact: Madeline Griffith (415) 476-7974: Madeline.Griffith@ucsf.edu

 

CC#194514: A Phase 2 Multicenter, Open-Label, Non-Randomized Study of Bavituximab Plus Pembrolizumab in Patients with Advanced Gastric or Gastroesophageal Cancer Who Have Progressed On or After At Least One Prior Standard Therapy

Contact: Malori Mindo (415) 502-6313: Malori.Mindo@ucsf.edu

 

CC#187011: A Phase 1/1b Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 424 in Subjects with Multiple Myeloma

Contact: Andrew Chon (415) 476-2351: Andrew.Chon@ucsf.edu 

 

CC#187012: A Phase I/II, Open-Label, Multicenter, Dose-Escalation and Dose Expansion Study of NKTR-262 in Combination with NKTR-214 and in Combination with NKTR-214 Plus Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumor Malignancies (Nektar Reveal 1 Study)

Contact: Andrew Chon (415) 476-2351: Andrew.Chon@ucsf.edu 

 

CC#19956: Protocol RMC 4360 02: A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of RMC-4630 in combination with Cobimetinib in Adult Participants with Relapsed/Refractory Solid Tumors
Contact: Claire Hooker (415) 353-7084: Claire.Hooker@ucsf.edu 

 

CC#19957: TRX518-004: A Dose Escalation and Expansion study of TRX518 in Combination with Cyclophosphamide Plus Avelumab in Advanced Solid Tumors
Contact: Claire Hooker (415) 353-7084: Claire.Hooker@ucsf.edu 

 

CC#19958: First-In-Human, Open-Label, Phase I Dose Escalation and Cohort Expansion Study of BB-1701 in Locally Advanced/Metastatic Her2 Expressing Solid Tumors
Contact: Claire Hooker (415) 353-7084: Claire.Hooker@ucsf.edu 

 

 


For information on Early Phase clinical trials not listed please contact:

Kamran Abri Lavasani (415) 514-6245: Kamran.AbriLavasani@ucsf.edu

For information on Immunotherapy trials not listed please contactAndrew Chon (415) 476-2351: Andrew.Chon@ucsf.edu